Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Bruton’s Tyrosine Kinase and Its Isoforms in Cancer
Xianhui Wang, Leila Kokabee, Mostafa Kokabee, et al.
Frontiers in Cell and Developmental Biology (2021) Vol. 9
Open Access | Times Cited: 35

Showing 1-25 of 35 citing articles:

Bruton’s Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials
Dariusz Rozkiewicz, Justyna Magdalena Hermanowicz, Iwona Kwiatkowska, et al.
Molecules (2023) Vol. 28, Iss. 5, pp. 2400-2400
Open Access | Times Cited: 49
Combination Approaches to Target PD-1 Signaling in Cancer
Emily K. Moore, Marianne Strazza, Adam Mor
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 27
The resistance mechanisms and treatment strategies of BTK inhibitors in B‐cell lymphoma
Haoran Wang, Wentao Zhang, Jingyi Yang, et al.
Hematological Oncology (2021) Vol. 39, Iss. 5, pp. 605-615
Open Access | Times Cited: 30
Recent development of BTK-based dual inhibitors in the treatment of cancers
Fansheng Ran, Yun Liu, Zhongyuan Xu, et al.
European Journal of Medicinal Chemistry (2022) Vol. 233, pp. 114232-114232
Closed Access | Times Cited: 22
Clinical Trials of the BTK Inhibitors Ibrutinib and Acalabrutinib in Human Diseases Beyond B Cell Malignancies
Sining Zhu, Jaeyong Jung, Eton Victor, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 24
Novel Therapies and Strategies to Overcome Resistance to Anti-HER2-Targeted Drugs
Manuel Gámez-Chiachio, David Sarrió, Gema Moreno‐Bueno
Cancers (2022) Vol. 14, Iss. 18, pp. 4543-4543
Open Access | Times Cited: 19
BTK inhibitors are a possible emerging therapeutic target for gastric cancer
José Darío Portillo‐Miño, Jhon Jairo Calderon, Arnoldo Riquelme
Deleted Journal (2025) Vol. 33, Iss. 1, pp. 200935-200935
Closed Access
Design and application of a fluorescent probe for imaging of endogenous Bruton’s tyrosine kinase with preserved enzymatic activity
Anna P. Valaka, Helena Filipsson Nyström, Liliana Håversen, et al.
RSC Chemical Biology (2025)
Open Access
Bruton’s Tyrosine Kinase: A Double-Edged Sword in Cancer and Aging
Zahraa Qusairy, Miran Rada
Kinases and Phosphatases (2025) Vol. 3, Iss. 2, pp. 10-10
Open Access
DEAD-Box RNA Helicases DDX3X and DDX5 as Oncogenes or Oncosuppressors: A Network Perspective
Massimiliano Secchi, Camilla Lodola, Anna Garbelli, et al.
Cancers (2022) Vol. 14, Iss. 15, pp. 3820-3820
Open Access | Times Cited: 15
An insight into the therapeutic impact of quinoxaline derivatives: Recent advances in biological activities (2020–2024)
Aly M. Waseem, Ranya Mohammed Elmagzoub, Mervat Mohammed Mazhar Abdelgadir, et al.
Results in Chemistry (2024), pp. 101989-101989
Open Access | Times Cited: 3
BTK, the new kid on the (oncology) block?
Emanuela Grassilli, Maria Grazia Cerrito, Marialuisa Lavitrano
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 11
Conformational heterogeneity of the BTK PHTH domain drives multiple regulatory states
David Yin-wei Lin, Lauren E. Kueffer, Puneet Juneja, et al.
eLife (2023) Vol. 12
Open Access | Times Cited: 6
Current Adenosinergic Therapies: What Do Cancer Cells Stand to Gain and Lose?
Jana Kotulová, Marián Hajdúch, Petr Džubák
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 22, pp. 12569-12569
Open Access | Times Cited: 14
Bruton’s tyrosine kinase inhibition attenuates disease progression by reducing renal immune cell invasion in mice with hemolytic-uremic syndrome
Sarah Kröller, Bianka Wissuwa, Sophie Dennhardt, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 5
Development and Characterization of Ibrutinib-Loaded Ethylcellulose-Based Nanosponges: Cytotoxicity Assay against MCF-7 Cell Lines
Farhat Fatima, Md. Khalid Anwer
Applied Sciences (2023) Vol. 13, Iss. 8, pp. 4984-4984
Open Access | Times Cited: 4
FDA-approved Abl/EGFR/PDGFR kinase inhibitors show potent efficacy against pandemic and seasonal influenza A virus infections of human lung explants
Robert Meineke, Sonja Stelz, Maximilian Busch, et al.
iScience (2023) Vol. 26, Iss. 4, pp. 106309-106309
Open Access | Times Cited: 4
Novel 5-Substituted Oxindole Derivatives as Bruton’s Tyrosine Kinase Inhibitors: Design, Synthesis, Docking, Molecular Dynamics Simulation, and Biological Evaluation
Vani Madhuri Velavalapalli, Venkatanarayana Chowdary Maddipati, Soňa Gurská, et al.
ACS Omega (2024)
Open Access | Times Cited: 1
mmu‐miR‐185 regulates osteoclasts differentiation and migration by targeting Btk
Dan He, Yueying Jiao, Jian Xu, et al.
The Journal of Gene Medicine (2024) Vol. 26, Iss. 5
Closed Access | Times Cited: 1
Covalent Targeting Drug Mediated Specific Lanthanide Tagging Towards In Situ Bruton's Tyrosine Kinase Quantification Using ICP-MS
Xiaowen Yan
Atomic Spectroscopy (2024) Vol. 45, Iss. 02, pp. 74-82
Open Access | Times Cited: 1
Expression analysis, molecular docking and molecular dynamics simulations to identify potential BTK inhibitors: strategy for targeting pan-cancer
Deepak Saravanan, Architha Vijayalakshmi, Shabnam Ameenudeen, et al.
Molecular Simulation (2024), pp. 1-11
Closed Access | Times Cited: 1
Conformational heterogeneity of the BTK PHTH domain drives multiple regulatory states
David Yin-wei Lin, Lauren E. Kueffer, Puneet Juneja, et al.
(2023)
Open Access | Times Cited: 3
Synthesis and Biological Evaluation of Oxindole Sulfonamide Derivatives as Bruton's Tyrosine Kinase Inhibitors**
Chandra Prakash Koraboina, Venkatanarayana Chowdary Maddipati, Narendran Annadurai, et al.
ChemMedChem (2023) Vol. 19, Iss. 1
Open Access | Times Cited: 3
Palmitoylation of the Alternative Amino Terminus of the BTK-C Isoform Controls Subcellular Distribution and Signaling
Mostafa Kokabee, Xianhui Wang, Elena Voorand, et al.
Cancer Genomics & Proteomics (2022) Vol. 19, Iss. 4, pp. 415-427
Open Access | Times Cited: 5
Development of novel hydrazidoarylaminopyrimidine-based BTK/FLT3 dual inhibitors with potent in vivo anti-hematological malignancies effects
Fansheng Ran, Xudong Xie, Qilin Wu, et al.
European Journal of Medicinal Chemistry (2022) Vol. 245, pp. 114913-114913
Closed Access | Times Cited: 5
Page 1 - Next Page

Scroll to top